A Phase III Randomized Study of Hypofractionated 3DCRT/IMRT versus Conventionally Fractionated 3DCRT/IMRT in Patients Treated for Favorable-Risk Prostate Cancer
Principal Investigator
W. Lee, MD MS
Status
Terminated
Date Closed to Accrual
December 11 2009
Date of Study Termination
December 22 2022
Disease Site
Genitourinary [GU]
Prostate
Phase
III
Developmental Therapeutics
No
Primary Objective
Patient Population
-
Target Accrual
1067
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.